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Background: Gastric cancer is the second most common cause of cancer-related death in males and the fourth in
females. Traditional treatment has poor prognosis because of recurrence and systemic side effects. Therefore, the
development of new therapeutic strategies is an important issue. Lentivirus-mediated shRNA stably inhibits target
genes and can efficiently transduce most cells. Since overexpressed cyclin D1 is closely related to human gastric
cancer progression, inhibition of cyclin D1 using specific targeting could be an effective treatment method of
human gastric cancer.
Methods: The therapeutic effect of lentivirus-mediated shRNA targeting of cyclin D1 (ShCCND1) was analyzed both
in vitro and in vivo experiments.
Results: In vitro, NCI-N87 cells with downregulation of cyclin D1 by ShCCND1 showed significant inhibition of cell
proliferation, cell motility, and clonogenicity. Downregulation of cyclin D1 in NCI-N87 cells also resulted in
significantly increased G1 arrest and apoptosis. In vivo, stable NCI-N87 cells expressing ShCCND1 were engrafted
into nude mice. Then, the cancer-growth inhibition effect of lentivirus was confirmed. To assess lentivirus including
ShCCND1 as a therapeutic agent, intratumoral injection was conducted. Tumor growth of the lentivirus-treated
group was significantly inhibited compared to growth of the control group. These results are in accordance with
the in vitro data and lend support to the mitotic figure count and apoptosis analysis of the tumor mass.
Conclusion: The lentivirus-mediated ShCCND1 was constructed, which effectively inhibited growth of NCI-N87-derived
cancer both in vitro and in vivo. The efficiency of shRNA knockdown and variation in the degree of inhibition is mediated
by different shRNA sequences and cancer cell lines. These experimental results suggest the possibility of developing
new gastric cancer therapies using lentivirus-mediated shRNA.
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Gastric cancer is the one of the most common causes of
cancer-related death all over the world. The survival of
gastric cancer patients has improved owing to improve-
ment in diagnostic and therapeutic tools [1]. However,
overall patient prognosis and long-term survival has not
significantly improved due to diagnosis of advanced stages
and the high rate of recurrence [2]. In addition, the bio-
logic heterogeneity of gastric cancer is one of the main* Correspondence: yangkyuc@konkuk.ac.kr
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reproduction in any medium, provided the orcauses of cancer therapy failure [3]. Therefore, it is neces-
sary to find a novel strategy to overcome gastric cancer.
Cyclin D1, a cell cycle regulator, is closely related to
several human cancers. Dysregulation of cyclin D1 immedi-
ately contributes to tumor progression in some animal
models, further demonstrating a connection between cyclin
D1 and carcinogenesis. Accordingly, inhibition of cyclin D1
may be an innovative strategy for cancer treatment [4,5].
Targeted therapy is becoming an important cancer ther-
apy. Although gene targeting has emerged as an important
treatment strategy of various malignant tumors in the past
decade, fewer targeted therapies for gastric cancer have
been studied compared to other cancers [6]. RNAi is one
of the most powerful targeted therapies to inhibit specific
gene expression at the post-transcriptional level. There. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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shRNA. Previous reports have demonstrated the following
limitations of siRNA: insufficient cellular uptake, in-
stability, rapid clearance in vitro, and inefficient deliv-
ery in vivo and in clinical settings [7-10]. However,
viral vector-mediated shRNA permit long-term stable
and consistent gene silencing [11]. Lentiviral vectors
of shRNA have been derived from HIV; the vectors can
express shRNA in mammalian cells [12,13]. These vectors
have been validated in clinical databases in animal models
of relevant cancers. Therefore, the lentivirus-mediated
shRNA strategy is an appealing candidate therapy for can-
cer treatment [14].
In this study, we hypothesized that inhibition of cyclin
D1 in human gastric cancer could suppress cancer pro-
gression in vitro and in vivo. To test this hypothesis, a
third-generation lentiviral vector was used to integrate
the shRNA sequence targeting cyclin D1 (ShCCND1) in
the human gastric cancer cell line NCI-N87. ShRNA was
expressed stably and consistently inhibited cyclin D1 ex-
pression. In vitro, the effect of silencing cyclin D1 on
gastric cancer cell function, including cell proliferation,
cell cycle, apoptosis, and cell motility was examined.
In vivo, stably ShCCND1-expressing NCI-N87 xenografts
were used to compare the growth rate with ShSramble
(shRNA-targeting scramble) cell xenografts. Next, the ef-
fect of intratumoral injection of these recombinant lentivi-
ruses targeting cyclin D1 on attenuation of the growth of
pre-existing cancer was assessed.
Methods
Cell lines and cell culture
NCI-N87 gastric carcinoma cells were purchased from
the Korean Cell Line Bank (KCLB, Seoul, Korea). Cells
were maintained in RPMI 1640 with 10% FBS and 1%
penicillin/streptomycin at 37°C, 5% CO2 within a hu-
midified chamber. The 293TN Human Kidney produ-
cer cell line was purchased from System Biosciences
(SBI, Mountain View, CA, USA). This cell line was main-
tained in DMEM high-glucose medium supplemented
with 10% FBS, Glutamax, and 1% penicillin/streptomycin
at 37°C, 5% CO2 within a humidified chamber.
ShRNA-expressing plasmid DNA
Three different targeted sequences designed to be hom-
ologous to cyclin D1 were designed using the lentiviral
expression vector (pGreenPuro™ Vector, SBI) [15]. Tar-
get sites in human genes encoding cyclin D1 were as fol-
lows: ShCCND1_1 sense strand, 5′-GCCCTCGGTGT
CCTACTTCAAAT-3′, ShCCND1_1 antisense strand,
5′-ATTTGAAGTAGGACACCGAGGGC-3′; ShCCND1_2
sense strand, 5′-GCACGATT TCATTGAACACTT
CC-3′, ShCCND1_2 antisense strand, 5′- GGAAGTGT
TCAATGAAATCGTGC-3′; ShCCND1_3 sense strand,5′-GAAGTTCATTTCCAATCCGCCCT-3, ShCCND1_3
antisense strand, 5′-AGGGCGGATTGGAAATGAAC
TTC-3′. These plasmid DNAs transcribed shRNA
with loop sequences of 5′-CTTCCTGTCAGA-3′. A
negative control sequence was also designed by the same
process, which had no homology with human proteins
(ShScramble sense strand, 5′-GACTTCATAAGGC
GCATGC-3′, ShScramble antisense strand, 5′-GCAT
GCGCCT TATGAAGTC-3′) [16]. Each DNA was
used to transform the E. coli strain DH5α and puri-
fied with a plasmid purification kit (Qiagen, Valencia,
CA, USA). The ligation product was confirmed by
PCR and sequencing.Lentivirus generation and establishment of the NCI-N87
cell line stably expressing shRNA
293TN cells were seeded at a density of 3 × 106 cells on
10-cm culture plates. After 24 h, successful co-transfection
of plasmid including the ShCCND1 or ShScramble with
lentiviral vector expression construct using lipofectamine
reagent was demonstrated. After 48 h, supernatant was
collected and added to PEG-it™ virus precipitation solution.
The supernatant/PEG-IT mixture was centrifuged 1,500 × g
for 30 min at 4°C and then resuspended in RPMI
medium at 1/100 of the original volume. One day
prior to transduction, NCI-N87 cells were plated in
24-well plates at 5 × 104 cells. After 24 h, NCI-N87
cells were infected with lentiviral particles containing
ShScramble or ShCCND1. The next day, NCI-N87
cells were cultured in RPMI 1640 medium including
puromycin (1 μg/ml). The expanded cells were then
used for further experiments. Transduction efficiency
of NCI-N87 cells with GFP signals were determined
by flow cytometry.Western blotting
Stable cancer cells (NCI-N87, ShScramble, and ShCCND1)
were lysed in RIPA buffer including protease inhibitor
(Sigma-Aldrich, St. Louis, MO, USA). The protein concen-
tration of cell lysate was determined using the BCA™ pro-
tein assay kit (Thermo Scientific, Rockford, IL, USA).
Equal amounts of total protein were electrophoresed by
10% SDS-PAGE, transferred onto nitrocellulose mem-
branes, and incubated with antibodies against cyclin D1
(1:500, Santa-Cruz Biotechnology, Santa Cruz, CA, USA),
pRB (1:200, Cell Signaling Technology, Beverly, MA, USA),
and β-actin (1:500, Santa-Cruz Biotechnology) at 4°C.
Membranes were then incubated with HRP-conjugated
anti-rabbit or anti-mouse secondary antibodies (1:1000,
Santa-Cruz Biotechnology). Signals were detected using
an ECL Test Kit (KPL, Gaithersburg, MD, USA). β-actin
served as the internal standard. Densitometric analysis
was performed using ImageJ software.
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The in vitro cell viability was analyzed using the CCK-8
assay (Dojindo Laboratories, Kumamoto, Japan). NCI-
N87, ShScramble, and ShCCND1 were seeded at a density
of 104 cells/well in 96-well plates. After 24 h, 10 μl of
CCK-8 was added to each well and incubated for 2 h. The
absorbance value was observed at 1, 2, 3, and 4 days using
an enzyme-linked immunosorbent assay (Tecan Sunrise,
Sunnyville, CA, USA).
To assess colony formation ability, NCI-N87 cells con-
taining shRNA were seeded at a density of 500 cells/well
in 6-well plates. After 3 weeks, cells were stained with
1% crystal violet. The number of colonies (≥25 cells) was
counted under a microscope. The relative number of
colonies in ShCCND1 was adjusted to the number in
ShScramble. Image analysis was conducted using Meta-
morph version 7.5.6.0 software (Molecular Devices,
Sunnyvale, CA, USA).
Scratch-wound healing assay
The scratch-wound healing assay was performed to de-
termine the role of cyclin D1 in cell migration [17].
NCI-N87 cells were plate on 60-mm plates at 5 × 104
cells. A scratch was made with a pipette tip when the
plate was almost filled with cells. After 48 h, the image
of cells that had migrated into the wounded area was
obtained by a Zeiss Axiovert 200 inverted microscope
(Carl Zeiss MicroImaging, Thornwood, NY, USA) with a
10× objective lens. The wound area was analyzed by
Metamorph version 7.5.6.0 software.
Cell cycle and apoptosis analysis
To determine the cell cycle distribution, 106 NCI-N87 cells
were washed twice with ice-cold PBS and resuspended in
PBS containing RNase A (Sigma-Aldrich) and PI (propi-
dium iodide, Sigma-Aldrich). Cells were incubated at
37°C in the dark for 1 h. The percentage of the cell
population in each phase of the cell cycle was measured
using FACSCalibur (Becton-Dickinson, Rutherford, NJ, USA),
and results were analyzed with the CELLQUEST software
(Becton-Dickinson).
To assess the apoptosis rate, NCI-N87 cells were starved
in FBS-free culture medium for 48 h. Then, aliquots
(100 μl) of 106 cells/ml were incubated with Annexin-V-
APC (allophycocyanin, BD Biosciencls Pharmingen, San
Diego, CA, USA) and PI (BD Biosciences Pharmingen) for
15 min in the dark. After incubation, 400 μl of the binding
buffer was added to the sample and then, samples were
analyzed by flow cytometry. The flow cytometric data
were analyzed with the CELLQUEST software.
Tumorigenecity in nude mouse
Male athymic BALB/c nude mice at 5 weeks of age were
purchased from the Nara Bio animal center (NARABiotech, Seoul, Korea). The mice were bred and main-
tained at the laboratory facility in Konkuk University
(Seoul, Korea). Tumorigenicity in nude mice was deter-
mined. The NCI-N87 cell line including ShScramble or
ShCCND1 was cultured with RPMI 1640 medium. Cells
(8 × 106) in 100 μl saline were subcutaneously injected
into the posterior right thigh. Tumor growth was mea-
sured by the tumor diameter with a digital vernier cali-
per three times a week from the 9th day until the 35th
day after tumor injection. Tumor volume (mm3) was
calculated according to the following equation: tumor
volume = d2 × D/2, where d and D represent the shortest
and the longest diameter, respectively. At the end of
the experiment (the 35th day), mice were sacrificed.
Tumorigenecity study was approved by the IACUC
(Institutional Animal Care and Use Committee) of Konkuk
University (KU12036).
Titration and intratumoral injection of lentivirus-mediated
ShCCND1 into established tumors
NCI-N87 cells were seeded at a density of 4 × 105 cells
per well in 6-well plates. After 24 h, cell culture medium
was replaced by RPMI 1640 medium including hexadi-
methrine bromide. Then, lentiviral stock in serial dilu-
tion was added to pre-plated NCI-N87 cells. After 48 h
incubation, analysis was performed by flow cytometer.
GFP-positive NCI-N87 cells were detected by flow cy-
tometry. Then, the virus titer was calculated by the
following equation: lentivirus titer in IU (infectious unit)/
ml = {(cell number at starting time) × (dilution factor) ×
(percent infection)}/(added virus volume expressed in ml).
To assess the inhibition effects of virus particle includ-
ing ShCCND1 on established tumors, male athymic
BALB/c nude mice (NARA Biotech, N = 20) at 5 weeks
of age were injected subcutaneously into the posterior
right thigh with 100 μl saline containing 4 × 106 NCI-
N87 cells. The mice were divided randomly into three
groups. Once tumors reached a volume of 80–100 mm3
(usually 6–8 days after injection of the cells), mice re-
ceived an intratumoral injection of 50 μl (4 × 107 IU/ml)
of saline (Saline, N = 6), virus containing ShScramble
(Virus_Scramble, N = 7), or virus containing ShCCND1
(Virus_CCND1, N= 7). After 1 week, Saline, Virus_Scramble,
or Virus_CCND1 was reinjected into the tumor mass.
In vivo therapeutic study was approved by the IACUC of
Konkuk University (KU13049).
H&E and TUNEL staining
At day 13 after the first intratumoral injection, the mice
were sacrificed and subcutaneous tumors were fixed in
10% neutral-buffered formalin. Fixed tumors were rou-
tinely processed for paraffin sectioning and H&E stain-
ing for histopathological examination. For quantification
of the mitotic count, mitotic figures were counted in five
Figure 1 Effect of ShCCND1 on cyclin D1 expression and cell
proliferation in NCI-N87 cells. Expression level of cyclin D1
protein in ShCCND1_3 was significantly inhibited in AGS cells by
western blotting (A). The viability of ShCCND1 demonstrated
significant inhibition of proliferation in NCI-N87 cells compared
to inhibition by ShScramble using the CCK-8 assay (B). The results
presented are the mean ± SEM. **P < 0.01 versus the
ShScramble-transduced cells.
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average number of mitotic figures per field. The detec-
tion of apoptosis was performed according to the in-
structions of the manufacturer (ApopTag, Chemicon
International Inc., Temecula, CA, USA). Briefly, the sec-
tions were deparaffinized and hydrated, and then treated
with proteinase K (20 μg/ml) in PBS (pH 7.5) at 37°C for
20 min followed by treatment with 3% hydroperoxidase
in PBS to block endogenous peroxidases. After washing
with PBS, the slides were incubated with terminal deoxy-
nucleotidyl transferase and nucleotide mixture at 37°C
for 1 h, and then anti-digoxigenin conjugate was added
for 30 min. The slides were treated with DAB before
counterstaining with hematoxylin. To measure the num-
ber of apoptotic cells, five fields at 400× magnification
per slide were quantitatively analyzed with the image
analyzer (Metamorph version 7.5.6.0 software). The data
were expressed as the average number of cells per field.
Statistical analysis
For statistical analysis, all data obtained were analyzed
using Prism 5 for Windows software (GraphPad Soft-
ware, San Diego, USA). Statistically significant differ-
ences between studied groups were evaluated using the
unpaired Student’s t-test and Fisher’s exact test. The re-
sults were determined to be significantly significant when
P < 0.05 was obtained.
Results
ShCCND1 significantly inhibited cyclin D1 expression and
cell proliferation in NCI-N87 cells
NCI-N87 cells infected with lentivirus were successfully
selected in medium containing puromycin (1 μg/ml).
The transduction efficiency of each cell line was 97.41%
(ShScramble) and 95.8% (ShCCND1) by flow cytometry
(data not shown). Western blotting was performed to as-
sess the role of ShCCND1 in cyclin D1 expression levels.
There was no difference in cyclin D1 expression levels
between NCI-N87 cells and ShScramble cells (data not
shown). In comparison with control, ShCCND1_1 and
ShCCND1_2 did not decrease protein levels of cyclin D1
(Figure 1A). In contrast, ShCCND1_3 resulted in de-
creased protein levels compared to NCI-N87 (31%).
Densitometric analysis of western blots identified a sig-
nificant (P < 0.01) decrease in ShCCND1_3 in NCI-N87
cells. The ShCCND1_3 cells were then used for sub-
sequent studies and referred to as ShCCND1. The ex-
pression level of pRB, a downstream molecule of cyclin
D1, showed significant inhibition in ShCCND1 (data not
shown). These data suggest that lentivirus-mediated
ShCCND1 could effectively inhibit endogenous cyclin D1
expression in NCI-N87 cells. To assess the inhibitory
effect of silencing cyclin D1 on cell proliferation, cell via-
bility was analyzed using the CCK-8 assay. ShCCND1exhibited dramatic inhibition of proliferation in NCI-N87
cells compared to ShScramble cells (Figure 1B). The sup-
pression of proliferation by ShCCND1 was more signifi-
cant at day 4 (P < 0.01). The viability of ShCCND1 was
lower than ShScramble during the experiment. These re-
sults confirmed that ShCCND1 inhibited proliferation of
the NCI-N87 human gastric cancer cells.
ShCCND1 inhibited colony formation and cell motility in
NCI-N87 cells
The colony formation assay was performed to test
whether ShCCND1 affected clonogenic potential, which
is an important characteristic of tumor growth in vivo
[18]. As shown in Figure 2A, ShCCND1 (N = 21.7) re-
sulted in smaller colony numbers compared to ShScram-
ble (N = 33.0, P < 0.05). These results indicate that
silencing cyclin D1 may prevent cell proliferation and in-
dicate that inhibition of cyclin D1 significantly decreased
the colony formation potential of cells, which correlates
with the formation of cancer in nude mouse [19]. The
motility of NCI-N87 cells was analyzed by the scratch-
wound healing assay because decreased clonogenic
potential is usually associated with invasion ability in
cancer cells [18]. In this assay, ShCCND1 showed a wider
wound area compared to ShScramble (Figure 2B). The
wound area was 30.1% and 21.9% in ShCCND1 and
ShScramble, respectively. The wound area of ShCCND1
was significantly decreased compared to ShScramble
Figure 2 Colony formation and scratch-wound healing assay.
Colony formation assays of ShCCND1 revealed a decrease in colony
number compared to that of ShScramble (A). The wound area of
ShCCND1 was significantly increased compared to the wound area
of ShScramble measured by the scratch-wound healing assay (B).
The data presented are the mean ± SEM. ***P < 0.001 versus the
ShScramble-transduced cells.
Figure 3 Effect of ShCCND1 on NCI-N87 cell cycle distribution
and apoptosis determined by flow cytometry. ShCCND1
significantly increased the G1 distribution of the cell cycle compared
to that of ShScramble (A). Apoptosis was significantly increased in
ShCCND1 compared to that of ShScramble (B). The data presented
are the mean ± SEM. **P < 0.01 and ***P < 0.001 versus the
ShScramble-transduced cells.
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have impaired migration capacity.
ShCCND1 affected cell cycle distribution and the
apoptosis rate
To identify the mechanism for the anti-proliferation ef-
fect, cell cycle distribution of ShCCND1 was analyzed.
As shown in Figure 3A, ShCCND1 induced a significant
G1 arrest in comparison with ShScramble (P < 0.001) due
to a reduction in the number of S phase cells (P = 0.058),
while there was little difference in the number of cells in
G2 phase. The G1 phase distribution of ShCCND1 was
67.2% in comparison with 50.17% in ShScramble. These
results suggest that ShCCND1 inhibits cell proliferation
by inducing Gl phase arrest. In addition to cell cycle ar-
rest, the rate of cellular apoptosis was examined by flow
cytometry. As shown in Figure 3B, ShCCND1 cells re-
sulted in a significant enhancement in apoptosis com-
pared to NCI-N87 cells. The cellular apoptosis rate was
29.19% in ShScramble and 48.14% in ShCCND1. There-
fore, knockdown of cyclin D1 significantly reduced apop-
totic cell death in NCI-N87 cells (P < 0.01).
ShCCND1 suppressed xenograft tumor growth in vivo
ShCCND1 inhibited the expression of cyclin D1 and
inhibited tumor cell growth in vitro. To further examine
the inhibitory effect of ShCCND1 on tumor cell growth
in vivo, a xenograft cancer model was used. As shown inFigure 4, tumors first appeared after 9 days, and tumor
growth inhibition was observed throughout the entire
experiment. At the end-point of the experiment, the dif-
ference was more evident; the last tumor volume was
2,348.2 ± 318.9 mm3 in the ShScramble group, whereas
the volume in the ShCCND1 group was 1,115.0 ±
457.7 mm3 (P < 0.001). The average tumor weight in the
ShScramble group was 2.3 ± 0.5 g compared to 0.6 ±
0.6 g in the ShCCND1 group. These data indicate that
lentivirus-mediated ShCCND1 can inhibit tumor growth
of NCI-N87 cells in nude mice.
Intratumoral injection of lentivirus-mediated ShCCND1
attenuated the growth of established cancer
To determine whether the lentivirus could efficiently in-
fect tumors and attenuate their growth, Virus_Scramble
and Virus_CCND1 were infected into NCI-N87-derived
cancer. Once tumors reached a volume of 80–100 mm3,
the cancer was injected with 50 μl of a Saline, Virus_Scramble,
or Virus_CCND1. The virus titer of Virus_Scramble and
Virus_CCND1 was 4 × 107 IU/ml. When experiments
were terminated for tumor harvesting, the NCI-N87-
derived cancer that was infected with Virus_CCND1 ex-
hibited a 45.6% (P < 0.01) and a 37.5% (P < 0.05) decrease
Figure 4 Effect of ShCCND1 on tumor growth in the xenograft mouse model. Gross observation of ShCCND1 xenografts showed a smaller
volume compared to that of ShScramble xenografts (A). Tumor volume of ShCCND1 xenografts was decreased compared to that of ShScramble
xenografts during the experiment (B). Tumor weight of ShCCND1 xenografts was significantly decreased compared to that of ShScramble
xenografts (C). The data presented are the mean ± SEM. **P < 0.01 and ***P < 0.001 versus the ShScramble-transduced cells.
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respectively (Figure 5). Furthermore, the weight of
Virus_CCND1-derived cancer was decreased by com-
parison with Saline and Virus_Scramble. The NCI-N87-
derived cancer that was infected with Virus_CCND1 ex-
hibited a 44.7% (P < 0.05) and a 34.9% (P < 0.05) decrease
in weight, by comparison with Saline and Virus_Scramble,
respectively. A statistically significant difference in cancer
volumes between Saline- and Virus_CCND1-injected
cancers was seen as early as five days after the viral injec-
tion (P < 0.01). Seven days after virus injection, there
was a significant difference in cancer volume between
Virus_Scramble and Virus_CCND1 (P < 0.05). Moreover,
the subsequent growth of all Virus_CCND1-injected tu-
mors remained significantly attenuated.
Intratumoral injection of lentivirus-mediated ShCCND1
inhibited proliferation and apoptosis in pre-existing
tumors
To determine the biological effect of Virus_CCND1, xeno-
graft sections were subjected to H&E or TUNEL staining.Figure 5 Effect of intratumoral injection with Saline, Virus_Scramble,
of Virus_CCND1 xenografts indicated a smaller volume than that of the Sal
xenografts was decreased compared to that of the Saline or Virus_Scrambl
xenografts was significantly decreased compared to that of Saline or Virus_
*P < 0.05 and **P < 0.01 versus Saline; #P < 0.05 versus Virus_Scramble.Treatment with Virus_CCND1 resulted in a significant de-
crease in the mitotic figure count compared to Saline and
Virus_Scramble (Figure 6, P < 0.001). There was a signifi-
cant induction in the mean number of TUNEL-positive
cells in Virus_Scramble compared to the Saline and
Virus_Scramble (P < 0.001). Taken together, these data
suggest that targeting cyclin D1 with lentivirus-mediated
ShCCDN1 could have an inhibition effect on cell prolifer-
ation and an induction effect of apoptosis in vivo on hu-
man gastric cancer.
Discussion
Cyclin D1 is one of the three D-type cyclins and has been
implicated in neoplastic function. The gene for cyclin D1 is
located on chromosome 11q13 and is related to various
cancers [20,21]. The increased expression of cyclin D1 has
been associated with decreased G1 phase distribution and
with decreased survival in many common cancers including
gastric cancer [22-25]. Inhibition of cyclin D1 expression
markedly suppressed cell proliferation and the beginning of
S phase in the cell cycle of many cancers [25,26].or Virus_CCND1 on established tumor growth. Gross observation
ine or Virus_Scramble xenografts (A). Tumor volume of Virus_CCND1
e xenografts during the experiment (B). Tumor weight of Virus_CCND1
Scramble xenografts (C). The data presented are the mean ± SEM.
Figure 6 Effect of intratumoral injection with Saline, Virus_Scramble, or Virus_CCND1 on proliferation and apoptosis in tumors. In H&E
staining, tumor tissues of Virus_CCND1 had decreased mitotic figure compared to that of Saline and Virus_Scramble, respectively. In the TUNEL
assay, the number of apoptotic cells of Virus_CCND1 were increased compared to the number of Saline and Virus_Scramble (A and B). Original
magnification, 400×. The data presented are the mean ± SEM. ***P < 0.001 versus Saline and ###P < 0.001 versus Virus_Scramble.
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ever, it is important to determine the most efficient
and straightforward delivery strategy of the siRNA. The
present study highlights the use of the shRNA-based tech-
nique, specifically the use of shRNA-based recombinant
lentiviral vector to produce siRNA [3,28].
Lentiviruses are in the genus of the retroviridae family,
which is an efficient vehicle for gene transduction and
integration. In contrast to other viral vectors, lentiviral
vectors have many advantageous. They have a lower im-
munogenicity, decreased likelihood of insertion muta-
genesis, the ability to efficiently infect both primary and
non-dividing cells, and a high capability of transgene in-
sertion. In addition, they have been used as efficient pre-
clinical models [14,29]. Therefore, they are ideally suited
as a silencing technique in human cancer cells [11].
In this study, ShCCND1 resulted in stable integration
of virus into the cellular genome and marked inhibition
of cyclin D1 protein levels. Our previous study also re-
ported that ShCCND1 significantly inhibited the expres-
sion levels of cyclin D1 and pRB, the major downstream
molecule of cyclin D1, in another gastric cancer cell,
AGS [30]. Downregulated of cyclin D1 was related to de-
creased cell proliferation, colony formation potential,
and cell motility in vitro. Downregulation of cyclin D1
was associated with both the cell cycle and apoptosis;
therefore, ShCCND1 significantly induced apoptosis and
G1 arrest. G1 phase arrest allows cells to either undergo
repair or enter the apoptotic pathway to maintain tissue
homeostasis and eliminate the mutated neoplastic and
hyperproliferating neoplastic cells from the system. In
recent years, the concept of cell cycle regulation-mediated
apoptosis has gained increasing attention, and it has
emerged as a potential way to inhibit cell growth [3,31].
As such, ShCCND1 may be a potent therapeutic agent by
causing G1 phase arrest and inducing apoptosis [32]. Col-
lectively, these results clearly demonstrate that the anti-
cancer effect of ShCCND1 NCI-N87 cells is mediated by
induction of cell cycle arrest and apoptosis.To analyze the therapeutic potential of the lentivirus
expressing ShCCND1, in vivo experiments were per-
formed. The recombinant lentivirus including ShCCND1
was intratumorally injected into established tumors.
Intratumoral injection of the recombinant lentivirus sup-
pressed the growth of established tumors arising from
NCI-N87 cells. This result demonstrates that downregu-
lation of cyclin D1 by the lentivirus-mediated shRNA
strategy resulted in a prolonged biological effect in vivo.
These results were also supported by the H&E and
TUNEL staining data. Mitotic figure is a marker of prolif-
eration and TUNEL-positive staining is a marker of apop-
tosis; results from these experiments suggested that
silencing of cyclin D1 inhibited cancer cell growth in vivo.
The decrease of mitotic figure count and increase in the
number of TUNEL-positive cells are consistent with the
known effects of silencing cyclin D1 and with the in vitro
data presented in this study.
There are several reasons that intratumoral injection
of lentivirus-mediated ShCCND1 may have diverse
advantageous effects. Targeting cyclin D1 could hinder
progress toward advanced cancer because cyclin D1 levels
increase in the relatively early stages of tumorigenesis
[33]. Furthermore, cyclin D1 is an essential component for
carcinogenesis in some cancers, which is supported by the
fact that cyclin D1 knockout mice do not make mammary
carcinomas in spite of the overexpression of c-neu and
v-Ha-ras [34]. Gastric cancer is characterized by the
interaction between cancer cells and stromal cells that con-
tain proliferating cancer-associated activated fibroblasts,
endothelial cells, and inflammatory cells. These stromal
cells have been suggested to confer a growth advantage to
gastric cancer cells within the tumor mass [35,36]. Direct
injection of Virus_CCND1 into gastric cancer would result
in a downregulation of cyclin D1 not only in cancer cells
but also in non-cancerous stromal cells. Therefore, direct
injection of Virus_CCND1 effectively inhibited gastric
cancer growth due to growth inhibition by simultaneously
blocking cancer cell and non-cancer cell growth. While
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http://www.biomedcentral.com/1471-2407/14/175intravenous injection of lentivirus showed histological
damage to the liver cells, intratumoral injection predom-
inantly infected the tumor instead of the liver and other
organs. In view of this fact, intratumoral injection of
the lentiviral vector is more advantageous than intra-
venous injection [37]. Intratumoral injection of lentivirus
should be generally applicable to human solid tumors
[38]. Therefore, direct injection of lentivirus-mediated
ShCCND1 is an efficient tool to significantly suppress
cyclin D1 in gastric cancer cells. But because this study
has some limitations, such as off-target effect or side-
effect of lentivirus-mediated ShCCND1 in vivo, further
study will be necessary to elucidate the accurate balance
between therapeutic efficacy and safety of lentivirus-
mediated ShCCND1 [39].
Conclusion
Taken together, intratumoral injection of lentivirus-mediated
ShCCND1 could efficiently inhibit gastric cancer growth
in vitro and in vivo. These results also present the exciting
possibility that this lentivirus-mediated ShCCND1 could
ultimately be delivered into established tumors of gastric
cancer patients by endoscopic ultrasonography, thereby
producing a new therapeutic strategy for advanced gastric
cancer. The silencing efficiency of shRNA varies based on
different shRNA sequences, shRNA expression cassettes,
and cancer cell lines [40,41], which is a disadvantage be-
cause it requires comprehensive bioinformatic and experi-
mental data to select the most effective shRNA against a
particular target. Therefore, these experimental results
suggest the possibility that lentivirus-mediated shRNA tar-
geting of cyclin D1 can be used as a new gastric cancer
therapy.
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